Difference between revisions of "Venlafaxine-agomelatine"

From Psychiatrienet
Jump to: navigation, search
Line 6: Line 6:
  
 
| start =  
 
| start =  
* '''Day 1:''' simultaneously start administration of agomelatine in a dosage of 25 mg/day.  
+
* '''Day 7:''' simultaneously start administration of agomelatine in a dosage of 25 mg/day.  
* '''Day 8:''' only continue administration of agomelatine. If necessary, increase dosage of agomelatine to 50 mg/day.}}
+
* '''Day 15:''' only continue administration of agomelatine. If necessary, increase dosage of agomelatine to 50 mg/day.}}

Revision as of 16:00, 17 July 2009

Venlafaxine
Type Antidepressant
Group SNRI
links
Medscape Venlafaxine
PubChem 5656
PubMed Venlafaxine
Kompas (Dutch) Venlafaxine
Wikipedia Venlafaxine
Agomelatine
Type Antidepressant
Group other
links
ATC-code N06AX22
EMEA valdoxan
PubChem 82148
PubMed Agomelatine
Kompas (Dutch) Agomelatine
Wikipedia Agomelatine

Switch medication from venlafaxine to agomelatine.

Nietinrijdenbord.png Stop venlafaxine
  • Day 1-14: gradually reduce dosage of venlafaxine to a maximum of 37,5 mg or 75 mg (slow release)/ day.
  • Day 15: stop administration of venlafaxine
Eenrichtingbord.png Start agomelatine
  • Day 7: simultaneously start administration of agomelatine in a dosage of 25 mg/day.
  • Day 15: only continue administration of agomelatine. If necessary, increase dosage of agomelatine to 50 mg/day.


The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.